UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 8.674

Sortiert nach

LGG-20. SELUMETINIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY OPTIC PATHWAY/HYPOTALAMIC LOW GRADE GLIOMA: A MONOINSTITUTIONAL EXPERIENCE

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Link zum Volltext

Verfügbarkeit prüfen

LGG-25. ADVANCING RESPONSE ASSESSMENT OF LOW-GRADE GLIOMAS: IDENTIFYING VOLUME CORRELATIONS OF BI-PERPENDICULAR DIAMETER CHANGES WITH MACHINE LEARNING

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Link zum Volltext

Verfügbarkeit prüfen

LGG-41. DECIPHERING PEDIATRIC LOW-GRADE GLIOMA TRAJECTORIES: DEEP LEARNING-BASED VOLUMETRICS FOR PATIENTS UNDER SURVEILLANCE

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Link zum Volltext

Verfügbarkeit prüfen

LGG-18. BEVACIZUMAB: GOOD FOR EYES AND MRI’S! A NATIONAL UK ASSESSMENT OF VISUAL AND RADIOLOGICAL OUTCOMES OF BEVACIZUMAB THERAPY IN PAEDIATRIC LOW-GRADE GLIOMA (PLGG)

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Link zum Volltext

Verfügbarkeit prüfen

LGG-07. MULTI-OMICS ANALYSIS IDENTIFIES MOLECULAR DRIVERS AND THERAPEUTIC TARGETS IN DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR WITH 1Q GAIN

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Link zum Volltext

Verfügbarkeit prüfen

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Suppl 3), p.iii375-iii375

2020

Link zum Volltext

Verfügbarkeit prüfen

Temozolomide-associated hypermutation in gliomas

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (10), p.1300-1309

2018

Link zum Volltext

Verfügbarkeit prüfen

LGG-45. Genetic dependencies inMYB/MYBL1-driven pediatric low-grade glioma models

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Suppl 1), p.i98-i98

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i93-i93

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i97-i98

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-46. Survival Of The Fittest? A Prognostic Evaluation of Paediatric Low-Grade Glioma (PLGG) Survivor Functional Outcomes

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i98-i99

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-02. Cardiac toxicity in patients receiving single-agent MEK inhibition

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i87-i87

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i87-i87

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-51. Resection extent and BRAF V600E mutation status determine postoperative growth velocity in pediatric Low-grade glioma: Results from a single-center cohort analysis

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i100-i100

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i97-i97

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-44. Multi-omic analysis reveals integrated signalling networks in paediatric low-grade glioma

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i98-i98

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-01. Children with Supratentorial Midline Pilocytic Astrocytomas Exhibit Multiple Progressions and Acquisition of Neurologic Deficits over Time

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i87-i87

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-33. A 40-year cohort study of evolving hypothalamic dysfunction in 90 infants and young children (<3y) with optic pathway gliomas

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i95-i95

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i90-i91

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-16. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i91-i91

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i96-i96

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-38. Dose-dependent seizure control for an NF1 patient treated via MEK-inhibition for optic pathway glioma

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i96-i97

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-54. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i101-i101

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i94-i94

2022

Link zum Volltext

Verfügbarkeit prüfen

LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i101-i101

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 8.674

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.536)
Mit Volltextzugriff
(8.125)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(177)
... seit 30 Tagen
(28)

Menü

Weitere Dienste

Einstellungen

LGG-20. SELUMETINIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY OPTIC PATHWAY/HYPOTALAMIC LOW GRADE GLIOMA: A MONOINSTITUTIONAL EXPERIENCE

LGG-25. ADVANCING RESPONSE ASSESSMENT OF LOW-GRADE GLIOMAS: IDENTIFYING VOLUME CORRELATIONS OF BI-PERPENDICULAR DIAMETER CHANGES WITH MACHINE LEARNING

LGG-41. DECIPHERING PEDIATRIC LOW-GRADE GLIOMA TRAJECTORIES: DEEP LEARNING-BASED VOLUMETRICS FOR PATIENTS UNDER SURVEILLANCE

LGG-18. BEVACIZUMAB: GOOD FOR EYES AND MRI’S! A NATIONAL UK ASSESSMENT OF VISUAL AND RADIOLOGICAL OUTCOMES OF BEVACIZUMAB THERAPY IN PAEDIATRIC LOW-GRADE GLIOMA (PLGG)

LGG-07. MULTI-OMICS ANALYSIS IDENTIFIES MOLECULAR DRIVERS AND THERAPEUTIC TARGETS IN DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR WITH 1Q GAIN

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)

Temozolomide-associated hypermutation in gliomas

LGG-45. Genetic dependencies inMYB/MYBL1-driven pediatric low-grade glioma models

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy

LGG-46. Survival Of The Fittest? A Prognostic Evaluation of Paediatric Low-Grade Glioma (PLGG) Survivor Functional Outcomes

LGG-02. Cardiac toxicity in patients receiving single-agent MEK inhibition

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas

LGG-51. Resection extent and BRAF V600E mutation status determine postoperative growth velocity in pediatric Low-grade glioma: Results from a single-center cohort analysis

LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma

LGG-44. Multi-omic analysis reveals integrated signalling networks in paediatric low-grade glioma

LGG-01. Children with Supratentorial Midline Pilocytic Astrocytomas Exhibit Multiple Progressions and Acquisition of Neurologic Deficits over Time

LGG-33. A 40-year cohort study of evolving hypothalamic dysfunction in 90 infants and young children (<3y) with optic pathway gliomas

LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study

LGG-16. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas

LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study

LGG-38. Dose-dependent seizure control for an NF1 patient treated via MEK-inhibition for optic pathway glioma

LGG-54. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma

LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold

Suchergebnisse filtern